autochthonous human disease. In July, 2019, a probable autochthonous case of tick-borne encephalitis in the UK was reported from an area close to where TBEV-UK-Hampshire was detected. 6 Tick-borne encephalitis diagnosis was based on serology data and, given the cross-reactivity with other flaviviruses endemic in the UK such as louping ill virus, a confirmatory diagnosis has not been possible.
The recent and contemporaneous nature of the detection of TBEV in two separate areas of the UK indicates that undetected TBEV foci might yet be identified. The results obtained from our work highlight the need for further research into the distribution and prevalence of TBEV in the UK. Furthermore, the medical community should be vigilant of the potential for TBEV infection in UK patients with no travel history, particularly when such patients present with a recent history of tick bite.
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Detection of tick-borne encephalitis virus in the UK
In 2019, we discovered the first evidence of tick-borne encephalitis virus (TBEV) in two areas of the UK. 1,2 These findings are important because they challenge previous climatic forecasts that had suggested TBEV would not establish in the UK.
The first detection of TBEV in the UK was confirmed in ticks collected in the Thetford Forest area of East Anglia during 2018. Sequence analysis indicated that the TBEV-UK-Thetford strain is closely similar to the Norwegian Mandal 2009 strain. 1 Although the Mandal strain has not been reported to be directly linked to human disease, there have been at least seven cases of tick-borne encephalitis reported in the Mandal area. 3 In addition, in an area where three patients contracted tick-borne encephalitis, surveys in Denmark identified a TBEV strain in the local tick population, the genome of which has close homology to TBEV-Mandal and TBEV-UK-Thetford. 4 The second detection of TBEV in the UK was in ticks on the border of Hampshire and Dorset in southern England. This virus is distinct from TBEV-UK-Thetford, but is closely homologous to a TBEV strain identified in the Netherlands, TBEV-NL-Salland, detected in 2017. 2 To date, there have been two autochthonous tick-borne encephalitis cases in the area of the Netherlands where TBEV-NL-Salland was detected. 3 The diversity of the TBEV strains indicates that there have been at least two separate importation events into the UK, possibly via the carriage of infected ticks on migratory birds.
There have been no confirmed autochthonous cases of tick-borne encephalitis in the UK. However, given that up to 60% of encephalitis cases in the UK have unknown causes, 5 TBEV could have already caused
Population-level impact of human papillomavirus vaccination
We read with interest the meta-analysis on the impact of human papillomavirus (HPV) vaccination programmes by Mélanie Drolet and colleagues. 1 The authors compared the pre-vaccination and post-vaccination frequency of outcomes related to HPV. They dichotomised studies on the basis of the proportion of people vaccinated in that country: either a medium or high proportion of people vaccinated (countries with a multiple age-cohort vaccination strategy and coverage ≥50%) or a low proportion (countries with a single-cohort strategy or coverage <50%). The results showed a substantial impact and herd protection of HPV vaccination programmes: multi-cohort vaccination with high coverage showed greater and faster effects than single-cohort vaccination or low coverage.
Our attention was drawn to the sensitivity analysis that showed substantially greater reductions in anogenital wart diagnoses for multicohort rather than single-cohort vaccination in high-coverage countries. However, in all three single-cohort studies analysed, vaccinated cohorts had not yet reached ages assessed in the meta-analysis for HPV endpoints (ie, in the third year post-vaccination, the first vaccinated cohorts had turned 14 years of age in the study by Thompson and colleagues, 2 15 years in the study by Cocchio and colleagues, 3 and 16 years in the study by Guerra and colleagues 4 ).
Without including a buffer period, we believe the impact of single-cohort strategies is being underestimated and cannot be directly compared with that of multi-cohort vaccination. This reasoning also questions whether single-cohort pre-post studies can really be categorised as having a low proportion of people vaccinated in the first post-vaccination years, as done in Drolet and colleagues' study. 1
